Rabin Medical Center
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 1936-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://rabin-medical.org
Clinical Trials
389
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (295 trials with phase data)• Click on a phase to view related trials
Effectiveness of Field Block Compared With Interscalene Block in Shoulder Surgery
- Conditions
- Regional Anesthesia Techniques in Shoulder Surgery
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 64
- Registration Number
- NCT07173894
- Locations
- 🇮🇱
Rabin medical center- Hasharon hospital, Petah Tikva, Central District, Israel
Assessing the Safety, Performance, and User Experience of the Tandem Mobi Automated Insulin Delivery System Among Young Competitive Athletes in Real-world Settings.
- Conditions
- Type 1 Diabetes
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT06979635
- Locations
- 🇮🇱
Schneider Children's Medical Center of Israel, Petach-Tikva, Israel
Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Injections
- Conditions
- Type 1 DiabetesType 2 Diabetes
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 45
- Registration Number
- NCT06966427
- Locations
- 🇮🇱
Schneider Children Medical Center of Israel, Petach Tikva, Israel
🇸🇮University Medical Center of Ljubljana, Ljubljana, Slovenia
Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Stage IV Without EGFR/ALK MutationNSCLC Adenocarcinoma
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06951399
- Locations
- 🇮🇱
Davidoff Comprehensive Cancer Center, Rabin Medical Center, Petah-Tikva, Israel
Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors
- Conditions
- Solid Tumors Refractory to Standard Therapy
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT06940349
- Locations
- 🇮🇱
Davidoff cancer center, RMC, Petah Tikva, Israel
- Prev
- 1
- 2
- 3
- 4
- 5
- 78
- Next
News
Can-Fite Receives IRB Approval for Phase IIa Pancreatic Cancer Trial of Namodenoson
Can-Fite BioPharma received Institutional Review Board approval from Rabin Medical Center to initiate a Phase IIa open-label study evaluating Namodenoson in advanced pancreatic adenocarcinoma patients.
CBD Shows Promise in Curbing SARS-CoV-2 Replication, Clinical Trials Needed
Early research suggests CBD may help curb SARS-CoV-2 replication in infected cells, warranting further investigation through rigorous clinical trials.